Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 4 of 84« First...23456...102030...Last »

Amgen Migraine Drug Wows in Late-Stage Study

Amgen’s migraine drug Aimovig continues to impress with its efficacy in late-stage clinical trials.

Read More »

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Potential for Improved Therapeutic Potency Versus Other Amyloid Beta-Directed Antibodies

ProMis Neurosciences Inc. reported further results of its previously announced and ongoing preclinical program for Alzheimer’s disease.

Read More »

Sound therapy may train brain to ignore tinnitus

A sound-emitting device worn in the ear during sleep may train the brain to ignore an annoying chronic ringing in the ears, a new study suggests.

Read More »

Toothpaste ingredient could fight malaria, research shows

Research carried out in part by an artificially intelligent ‘robot scientist’ found that a common ingredient of toothpaste could be developed to fight drug-resistant strains of malaria.

Read More »

Chemo organ bath improves ovarian cancer survival

A heated chemotherapy organ bath circulated throughout the abdomen after surgery can significantly prolong a woman’s survival with advanced ovarian cancer.

Read More »

Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib

Cabozantinib provided a statistically significant and clinically meaningful improvement versus placebo in overall survival at the planned second interim analysis for the population of second-line and third-line patients enrolled in the CELESTIAL study.

Read More »

Eiger to abandon blood pressure drug

Eiger BioPharmaceuticals Inc. will stop development of a drug to treat pulmonary arterial hypertension after it failed in a mid-stage study.

Read More »

Keytruda extends lung cancer survival in study

A cocktail of Merck & Co. Inc.’s blockbuster drug Keytruda and two chemo medicines helped lung cancer patients live longer and stopped the disease from advancing.

Read More »

Novartis new data reinforces superiority of Cosentyx versus Stelara in achieving skin clearance for psoriasis patients

Novartis announced results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx (secukinumab) compared to Stelara (ustekinumab) in delivering clear and almost clear skin in adults with moderate to severe plaque psoriasis at 12 weeks.

Read More »

Smaller social network tied to bigger diabetes risk

Socially isolated people may be more likely to develop diabetes than adults with closer ties to family and friends, a recent study suggests.

Read More »

Human antibodies made in cows could be developed to treat MERS

Human antibodies made in genetically engineered cows have proved safe in an early-stage clinical trial.

Read More »

Momenta, Mylan plan biosimilar clinical trial

Momenta Pharmaceuticals and Mylan plan to begin a pivotal clinical study of a biosimilar to Regeneron’s blockbuster eye drug Eylea in first-half 2018.

Read More »

Sangamo, Pfizer to develop gene therapy for ALS

Sangamo Therapeutics Inc. and Pfizer Inc. are partnering to develop a gene therapy to treat a disease that affects nerve cells in the brain and the spinal cord.

Read More »

Immune cells linked to very early spread of breast cancer

Normal immune cells that live near milk ducts in healthy breast tissue may play a key role in helping early breast cancer cells leave the breast for other parts of the body, researchers say.

Read More »

Starting new COPD inhaler tied to heart attack risk

People with chronic obstructive pulmonary disease (COPD) who use long-acting inhaled bronchodilators may have an increased risk of heart attacks and strokes right after they start taking these medicines, a Taiwanese study suggests.

Read More »

Drinking hot tea linked to lowered glaucoma risk

People who drink hot tea daily may be less likely than others to develop glaucoma symptoms, U.S. researchers say.

Read More »

Odonate Therapeutics Announces Initiation of Phase 3 Study for Metastatic Breast Cancer

Odonate Therapeutics Inc. announced that it has initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer.

Read More »

Supplements may not lower fracture risk

Older adults who take vitamin D and calcium are no less likely to break their hips or other bones than peers who do not use these supplements per a research review.

Read More »

Celgene’s Follicular Lymphoma Regimen Fails Phase III

Shares of Celgene plunged after the company announced Revlimid combined with Biogen’s Rituxan failed in a late-stage study of previously untreated patients with follicular lymphoma.

Read More »

Three Hottest Areas of Drug Development to Keep an Eye on in 2018

The last several years has shown a particular focus on immuno-oncology therapies, probably as close to miracle cures as anything seen in recent years. Arpita Dutt, writing for Zacks, predicts what the three hot areas for approvals are likely to be in 2018.

Read More »

Page 4 of 84« First...23456...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation